Kee-Hong Kim

Kee-Hong Kim, Ph.D., currently serves as Chief Technology Officer and Senior Vice President of Manufacturing and Technical Operations at Tenaya Therapeutics, focusing on gene and other therapies for heart diseases since October 2018. Previously, Kee-Hong held the position of Senior Vice President and Head of Technical Operations at Agilis Biotherapeutics Inc., where significant contributions included the successful approval of Agil-AADC (UPSTAZA) by EMA. Kee-Hong's extensive experience encompasses roles at Shire and KDS Biopharma Consulting, specializing in gene therapy across various therapeutic areas and leading CMC filings to regulatory agencies. Additional professional background includes positions at Avalanche Biotechnologies, Dendreon Corporation, and Aeras Global TB Vaccine Foundation, fostering expertise in process development and cGMP manufacturing. Kee-Hong Kim earned a Ph.D. in Biochemical Engineering from Colorado State University.